Novavax's (NVAX) COVID-19 Vaccine Shows Final Efficacy of 96.4%

[red-beard]

https://finance.yahoo.com/news/novavaxs-nvax-covid-19-vaccine-130301820.html

Novavax, Inc.’s NVAX final data from a pivotal phase III study evaluating its coronavirus vaccine candidate, NVX-CoV2373, showed that it was 96.4% effective against mild, moderate and severe disease caused by the original COVID-19 strain in the United Kingdom.

The company also announced results from the complete analysis of its phase IIb study in South Africa. In the region marked by a vast majority of strains that are B1.351 escape variants, the vaccine candidate delivered 55.4% efficiency among the HIV-negative study participants.

Importantly, both studies conducted by the company have met statistical success parameters. Also, NVX-CoV2373 demonstrated 100% protection against severe disease and significantly reduced mild and moderate diseases across both the studies.

Novavax is planning to submit the data for authorization to several regulatory agencies worldwide.